A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD and/or HSDD.

Trial Profile

A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD and/or HSDD.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2015

At a glance

  • Drugs Bremelanotide (Primary)
  • Indications Female sexual dysfunction
  • Focus Therapeutic Use
  • Sponsors Palatin Technologies
  • Most Recent Events

    • 01 May 2014 Responder analysis published in the Obstetrics and Gynecology.
    • 01 Mar 2013 Results were presented at the International Society for the Study of Women's Sexual Health (ISSWSH) conference in March 2013.
    • 08 Nov 2012 Status changed from active, no longer recruiting to completed, according to a Palatin Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top